WNT

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

Retrieved on: 
Wednesday, March 27, 2024
Toxicity, Ovarian cancer, BRCA, Mirvetuximab soravtansine, Partnership, Patient, Neoplasm, Cancer, Merck, Doctor of Philosophy, Olaparib, WNT, Niraparib, Jiangsu Hengrui Medicine, PARP, Therapy, Safety, Platinum, Interim, Rucaparib, Pharmaceutical industry

This decisive shift in priorities is driven by the compelling initial data from the Phase 2 monotherapy trial evaluating stenoparib in advanced, recurrent ovarian cancer patients, as announced on December 5, 2023.

Key Points: 
  • This decisive shift in priorities is driven by the compelling initial data from the Phase 2 monotherapy trial evaluating stenoparib in advanced, recurrent ovarian cancer patients, as announced on December 5, 2023.
  • In addition, stenoparib is unique in its mechanism of action, inhibiting PARP as well as the novel cancer target, tankyrase.
  • Tankyrase inhibition would restrain the WNT pathway, which is commonly upregulated not only in ovarian cancers but in many other solid cancers.
  • Given the unique, dual mechanism of action for stenoparib—coupled with its favorable safety profile—stenoparib may represent the next-generation alternative in the evolving market for advanced ovarian cancer patients.

Iterion Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Tegavivint in Patients with Advanced Hepatocellular Carcinoma Who Have Failed One or More Systemic Treatments

Retrieved on: 
Tuesday, February 20, 2024
NCI, Neoplasm, WNT, FDA, Drug development, Overalls, Metastasis, National Cancer Institute, Death, Survival rate, Prevalence, Safety, Prognosis, Therapy, Plantar fibromatosis, Patient, Clinical trial, Transducin, Trial of the century, HCC, Cancer, Pharmaceutical industry

Unfortunately, key members of this pathway (including beta-catenin) have either been resistant to conventional drug development or plagued with off-target toxicities.

Key Points: 
  • Unfortunately, key members of this pathway (including beta-catenin) have either been resistant to conventional drug development or plagued with off-target toxicities.
  • Extensive pre-clinical study results across multiple tumor types suggest that TBL1 is a downstream target that is necessary for Wnt/beta-catenin-activated oncogenesis.
  • Tegavivint has demonstrated safety, clinical and pharmacodynamic activity in a Phase 1 clinical study of patients with desmoid tumors.
  • For more information about this Phase 1b/2a clinical trial of tegavivint in patients with advanced HCC, please visit www.ClinicalTrials.gov using the identifier NCT05797805.

AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy

Retrieved on: 
Thursday, February 15, 2024
Scar, Brock University, Myotonic dystrophy, AMO, Zebrafish, WNT, Hamilton Health Sciences, SCD, Duchenne muscular dystrophy, Tideglusib, Facial muscles, McMaster University, Risk, Health, ICD, Phenotype, DSM-IV codes, Patient, Arrhythmogenic cardiomyopathy, Target, MOA, Hiro, ACM, Research, Pharmaceutical industry

Enrollment is set to begin in mid-2024 at 20 sites across Canada and will include a total of 120 participants who will be randomized in a 1:1 ratio.

Key Points: 
  • Enrollment is set to begin in mid-2024 at 20 sites across Canada and will include a total of 120 participants who will be randomized in a 1:1 ratio.
  • The TaRGET trial is a critical first step in evaluating this potential."
  • This scarring increases the risk of dangerously fast heart rhythms that can lead to sudden cardiac death (SCD).
  • An implantable cardioverter defibrillator (ICD) is recommended for prevention of SCD for ACM patients considered at high risk for SCD.

AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy

Retrieved on: 
Thursday, February 15, 2024
Scar, Brock University, Myotonic dystrophy, AMO, Zebrafish, WNT, Hamilton Health Sciences, SCD, Duchenne muscular dystrophy, Tideglusib, Facial muscles, McMaster University, Risk, Health, ICD, Phenotype, DSM-IV codes, Patient, Arrhythmogenic cardiomyopathy, Target, MOA, Hiro, ACM, Research, Pharmaceutical industry

Enrollment is set to begin in mid-2024 at 20 sites across Canada and will include a total of 120 participants who will be randomized in a 1:1 ratio.

Key Points: 
  • Enrollment is set to begin in mid-2024 at 20 sites across Canada and will include a total of 120 participants who will be randomized in a 1:1 ratio.
  • The TaRGET trial is a critical first step in evaluating this potential."
  • This scarring increases the risk of dangerously fast heart rhythms that can lead to sudden cardiac death (SCD).
  • An implantable cardioverter defibrillator (ICD) is recommended for prevention of SCD for ACM patients considered at high risk for SCD.

HotelPlanner Partners with the World Nineball Tour as Official Hotel Provider

Retrieved on: 
Thursday, January 18, 2024
WNT, Gymnastics, Partnership, Athlete, Sport, PALM

WEST PALM BEACH, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- HotelPlanner, a leading travel technology platform and hotel booking engine, today announced a service provider partnership with the World Nineball Tour, the world’s first professional, commercial pool tour.

Key Points: 
  • WEST PALM BEACH, Fla., Jan. 18, 2024 (GLOBE NEWSWIRE) -- HotelPlanner, a leading travel technology platform and hotel booking engine, today announced a service provider partnership with the World Nineball Tour, the world’s first professional, commercial pool tour.
  • HotelPlanner and Matchroom Multi Sport will focus their initial partnership on the World Nineball Tour , a professional billiards tour with more than 30 annual events across five continents, including the Matchroom Majors, Matchroom Invitationals and the World Pool Championship.
  • The World Nineball Tour provides a unique commercial platform for professional pool players, similar to partner’s World Snooker Tour Ltd. and the Professional Darts Corporation, which have both awarded millions in prize money.
  • So we’re very proud to welcome Matchroom Multi Sport and the World Nineball Tour to the HotelPlanner family.”

Surrozen Provides Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 8, 2023
Research, Patent, Therapy, Workforce, Development, Regeneration, Boehringer Ingelheim, Partnership, Administration, Retina, SAN, Pharmaceutical industry, Cryptocurrency, WNT

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today provided third quarter 2023 financial results and business updates.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today provided third quarter 2023 financial results and business updates.
  • Financial Results for the Third Quarter Ended September 30, 2023
    Cash Position: Cash, cash equivalents and marketable securities were $43.4 million as of September 30, 2023, compared to $53.4 million as of June 30, 2023.
  • General and administrative expenses include non-cash stock-based compensation expenses of $0.7 million for the third quarter ended September 30, 2023 and 2022.
  • Net Loss: Net loss for the third quarter ended September 30, 2023 was $10.4 million, as compared to $13.4 million for the same period in 2022.

Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action

Retrieved on: 
Monday, October 30, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, FDA, Growth, RAS, NYSE, Food, Hope, Pathology, European Medicines Agency, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Disease, CANF, EMA, Pancreatic cancer, NF-κB, TASE, Safety, Hepatology, Apoptosis, Patient, Death, Cancer, Pharmaceutical industry, WNT

The article includes a summary on the robust inhibition of pancreatic carcinoma growth, both in vitro and in vivo and a definitive description of the molecular mechanism of action.

Key Points: 
  • The article includes a summary on the robust inhibition of pancreatic carcinoma growth, both in vitro and in vivo and a definitive description of the molecular mechanism of action.
  • This mechanism is highly important since pancreatic carcinoma cells are resistant to the chemotherapy.
  • “We are very much encouraged by the excellent data in the pre-clinical studies demonstrating the impressive anti-cancer effect of Namodenoson against pancreatic carcinoma,” stated Dr. Fishman, Can-Fite’s Chief Scientific Officer and Executive Chairman.
  • “We plan to start treating patients very shortly and hope that Namodenoson, with its positive safety and efficacy profile, will prolong life for pancreatic cancer patients.”

Cytovation Reports Promising Interim Results from Phase 1/2a CICILIA Study with CyPep-1 in Solid Tumors

Retrieved on: 
Wednesday, October 11, 2023
Doctor of Philosophy, Adrenocortical carcinoma, European Society for Medical Oncology, MD, Liver disease, ACC, Large intestine, WNT, Part, Neoplasm, Patient, Medical imaging, Pharmaceutical industry

Approx 20% of all solid tumor types are driven by aberrant Wnt/β-catenin signaling.

Key Points: 
  • Approx 20% of all solid tumor types are driven by aberrant Wnt/β-catenin signaling.
  • Cytovation to investigate CyPep-1 in further clinical trials starting with Adrenocortical Carcinoma (ACC) with aim to unlock its potential in a broad range of solid tumors.
  • Cytovation is planning to start a Phase 2 trial in ACC in 2024 with registrational intent.
  • This strategy provides a fast and cost-effective route to market, while validating the broader potential of the CyPep-1 platform for future development indications in β-catenin-driven solid tumors.

Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)

Retrieved on: 
Wednesday, September 27, 2023
Oncology, Health, Diabetes, Clinical Trials, Pharmaceutical, Biotechnology, KRAS, AACR, Hepatology, Progression-free survival, CSO, Safety, Pancreatic cancer, Pathology, Cancer, WNT, Patient, CANF, TASE, Growth, Poster, Conference, NYSE, Pharmaceutical industry

Can-Fite BioPharma Ltd .

Key Points: 
  • Can-Fite BioPharma Ltd .
  • The pre-clinical studies presented in the poster used advanced pancreatic carcinoma patient cells that were treated with Namodenoson both in tissue cultures and in in vivo studies.
  • Namodenoson treatment resulted in a significant growth inhibition and de-regulation of two signal transduction pathways, the Wnt and the KRAS, both of which are responsible for the etiology and pathology of this devastating disease.
  • “The robust inhibition of pancreatic carcinoma growth both in vitro and in vivo, together with the definitive mechanism of action is a strong basis for evaluating Namodenoson in patients with pancreatic carcinoma where chemotherapeutic drugs have a very limited effect.

Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Retrieved on: 
Thursday, August 31, 2023
FDA, Health, Diabetes, Clinical Trials, Pharmaceutical, Biotechnology, Pancreatic cancer, Oculocerebrorenal syndrome, University, Journal of Clinical Oncology, Hepatology, University of Naples Federico II, Liver cancer, DSM-IV codes, European Medicines Agency, IDMC, American Society of Clinical Oncology, Survival, Policy, History, WNT, Cancer, Psoriasis, ASCO, EMA, Journal, Patient, Pancreas, CANF, Treatment, TASE, Adolescence, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CKD, SLD, NYSE, HCC, Safety, Food, A3, Society, Medical imaging, Pharmaceutical industry, Cryptocurrency, Life insurance, Medicine, Genetics

In pre-clinical studies, Namodenoson demonstrated a robust anti-growth effect against pancreatic carcinoma, reaching 90% growth inhibition.

Key Points: 
  • In pre-clinical studies, Namodenoson demonstrated a robust anti-growth effect against pancreatic carcinoma, reaching 90% growth inhibition.
  • The FDA requested two Phase III studies and also encouraged the Company to enroll adolescent patients due to Piclidenoson’s strong safety profile demonstrated over its development history and prior clinical studies.
  • The decrease in cash during the six months ended June 30, 2023 is due to the ongoing operations of the Company.
  • The Company's consolidated financial results for the six months ended June 30, 2023 are presented in accordance with US GAAP Reporting Standards.